Drug-related jaw necrosis
Conditions
Interventions
Queue A (Bone-modifying drugs have been used):None
Queue B (Diagnosed as MRONJ):None
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Queue A: Age >= 18 years old; 2. Queue A: Patients who plan to start or have already used bone-modifying drugs (including bisphosphonates and denosumab), anti-angiogenic drugs such as bevacizumab and aflibercept, and tyrosine kinase inhibitors such as sunitinib); 3. Queue A: Voluntarily join and sign the informed consent; 4. Queue B: Age >= 18 years old; 5. Queue B: Patients diagnosed with MRONJ according to AAOMS and have not been cured yet; 6. Queue B: Voluntarily join and sign the informed consent;
Exclusion criteria
Exclusion criteria: 1.Queue A:Diagnosed with MRONJ; 2.Queue A:Radiation necrosis or metastatic bone disease of the jaw; 3.Queue A:Unable to complete follow-up, missing information in medical history; 4.Queue A:during pregnancy; 5.Queue B:History of radiation therapy for the head and neck; 6.Queue B:Metastatic bone disease in the maxillofacial region; 7.Queue B:Unable to complete follow-up, missing information in medical history; 8.Queue B:during pregnancy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Queue B: Cured using ordinal classification 20 (H1);Queue A: Newly diagnosed MRONJ (based on AAOMS criteria); | — |
Secondary
| Measure | Time frame |
|---|---|
| Queue A: Increased CBCT composite radiation index score;Queue B: CBCT or clinical examination reveals spontaneous separation of dead bone; | — |
Countries
China
Contacts
Public ContactZhu Wenxuan
China-Japan Friendship Hospital
Outcome results
None listed